Meryx Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

Meryx General Information

Description

Developer of therapeutics intended to inhibit growth and initiate anti-tumor immunity in a range of hematologic and solid malignancies The company develops orally bioavailable inhibitors targeting receptor tyrosine kinases with the potential to both inhibit tumor growth and initiate anti-tumor immunity in a wide range of cancers such as leukemia, lung cancer, and melanoma, enabling clinicians to treat cancer and other diseases.

Contact Information

Website
www.meryxpharma.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 510 Meadowmont Village Circle
  • Suite 359
  • Chapel Hill, NC 27517
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Xcovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 510 Meadowmont Village Circle
  • Suite 359
  • Chapel Hill, NC 27517
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Meryx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 07-Dec-2021 Completed Generating Revenue
2. Seed Round 29-Jun-2015 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 29-Dec-2014 $4.65M $4.65M Completed Pre-Clinical Trials
To view Meryx’s complete valuation and funding history, request access »

Meryx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Meryx’s complete cap table history, request access »

Meryx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutics intended to inhibit growth and initiate anti-tumor immunity in a range of hematologic and soli
Drug Discovery
Chapel Hill, NC
3 As of 2015

Lexington, MA
 

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Meryx Competitors (61)

One of Meryx’s 61 competitors is Cyteir Therapeutics, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cyteir Therapeutics Formerly VC-backed Lexington, MA
NexImmune Formerly VC-backed Gaithersburg, MD
TScan Therapeutics Formerly VC-backed Waltham, MA
Kite Pharma Formerly VC-backed Santa Monica, CA
AnTolRx Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 61 competitors. Get the full list »

Meryx Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Meryx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220162214-A1 Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications Pending 02-Apr-2019
AU-2020256186-A1 Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications Pending 02-Apr-2019
EP-3947389-A4 Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications Pending 02-Apr-2019
EP-3947389-A1 Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications Pending 02-Apr-2019
CA-3146343-A1 Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications Pending 02-Apr-2019 C07D487/04
To view Meryx’s complete patent history, request access »

Meryx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Meryx Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eshelman Ventures Venture Capital Minority
Angel (individual) Minority
To view Meryx’s complete investors history, request access »

Ready to get started?

Request a free trial

Meryx FAQs

  • When was Meryx founded?

    Meryx was founded in 2013.

  • Where is Meryx headquartered?

    Meryx is headquartered in Chapel Hill, NC.

  • What is the size of Meryx?

    Meryx has 3 total employees.

  • What industry is Meryx in?

    Meryx’s primary industry is Drug Discovery.

  • Is Meryx a private or public company?

    Meryx is a Private company.

  • What is Meryx’s current revenue?

    The current revenue for Meryx is .

  • How much funding has Meryx raised over time?

    Meryx has raised $7.15M.

  • Who are Meryx’s investors?

    Eshelman Ventures and have invested in Meryx.

  • Who are Meryx’s competitors?

    Cyteir Therapeutics, NexImmune, TScan Therapeutics, Kite Pharma, and AnTolRx are some of the 61 competitors of Meryx.

  • When was Meryx acquired?

    Meryx was acquired on 07-Dec-2021.

  • Who acquired Meryx?

    Meryx was acquired by Xcovery.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »